Wolfgang Köhler1. 1. Fachkrankenhaus Hubertusburg, Klinik für Neurologie und Neurologische Intensivmedizin, Wermsdorf, Germany. wolfgang.koehler@kh-hubertusburg.de
Abstract
PURPOSE OF REVIEW: Knowledge of the metabolic and genetic basis of known and previously unknown leukodystrophies is constantly increasing, opening new treatment options such as enzyme replacement or cell-based therapies. This brief review highlights some recent work, particularly emphasizing results from studies in adulthood leukodystrophies. RECENT FINDINGS: Evidence from recent studies suggests increasing importance of metabolic dysfunctions, for example, in peroxisomal lipid metabolism or energy homeostasis, influencing axonal integrity and oligodendrocyte function and leading to white matter demyelination. In addition, diagnostic and therapeutic progress in metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Krabbe diseases and other rare leukodystrophies with late onset are summarized. SUMMARY: Better understanding of leukodystrophies in neurological routine practice is of crucial importance for differentiating between other white matter diseases such as toxic, inflammatory or vascular leukoencephalopathies. Many leukodystrophies are particularly important to recognize because specific treatments already exist or are currently under investigation. The article also provides an overview of currently known leukodystrophies in adulthood.
PURPOSE OF REVIEW: Knowledge of the metabolic and genetic basis of known and previously unknown leukodystrophies is constantly increasing, opening new treatment options such as enzyme replacement or cell-based therapies. This brief review highlights some recent work, particularly emphasizing results from studies in adulthood leukodystrophies. RECENT FINDINGS: Evidence from recent studies suggests increasing importance of metabolic dysfunctions, for example, in peroxisomal lipid metabolism or energy homeostasis, influencing axonal integrity and oligodendrocyte function and leading to white matter demyelination. In addition, diagnostic and therapeutic progress in metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Krabbe diseases and other rare leukodystrophies with late onset are summarized. SUMMARY: Better understanding of leukodystrophies in neurological routine practice is of crucial importance for differentiating between other white matter diseases such as toxic, inflammatory or vascular leukoencephalopathies. Many leukodystrophies are particularly important to recognize because specific treatments already exist or are currently under investigation. The article also provides an overview of currently known leukodystrophies in adulthood.
Authors: Patricia de Monasterio-Schrader; Olaf Jahn; Stefan Tenzer; Sven P Wichert; Julia Patzig; Hauke B Werner Journal: Cell Mol Life Sci Date: 2012-03-23 Impact factor: 9.261
Authors: Sebastian Werneburg; Hazel L S Fuchs; Iris Albers; Hannelore Burkhardt; Viktoria Gudi; Thomas Skripuletz; Martin Stangel; Rita Gerardy-Schahn; Herbert Hildebrandt Journal: J Neurosci Date: 2017-07-31 Impact factor: 6.167
Authors: Joseph J Orsini; Denise M Kay; Carlos A Saavedra-Matiz; David A Wenger; Patricia K Duffner; Richard W Erbe; Chad Biski; Monica Martin; Lea M Krein; Matthew Nichols; Joanne Kurtzberg; Maria L Escolar; Darius J Adams; Georgianne L Arnold; Alejandro Iglesias; Patricia Galvin-Parton; David F Kronn; Jennifer M Kwon; Paul A Levy; Joan E Pellegrino; Natasha Shur; Melissa P Wasserstein; Michele Caggana Journal: Genet Med Date: 2016-01-21 Impact factor: 8.822